Table 2.
Combination of anti-PfCSP and anti-PfTRAP can improve sterile protection from mosquito-bite challenge.
| Sterile protectiona Exp 1 | Sterile protectiona Exp 2 | Sterile protectiona Exp 3 | Sterile protectiona Combined | Comparison p valueb vs. 150 µg mIgG | Comparison p valueb vs. 50 µg αCSP | |
|---|---|---|---|---|---|---|
| 150 μg mIgGc | 0/7 (0%)d | 0/7 (0%)d | 0/5 (0%) | 0/19 (0%) | – | <0.0001 |
| 50 μg AKBR-4 | 0/6 (0%) | – | 0/5 (0%) | 0/11 (0%) | 1 | 0.0002 |
| 50 μg αCSP | 5/7 (71%)d | 5/8 (63%)d | 5/8 (63%) | 15/23 (65%) | <0.0001 | – |
| 150 μg αCSP | – | 3/5 (60%) | – | 3/5 (60%) | 0.002 | 0.88 |
| 50 μg AKBR-4 + 50 μg αCSP | – | 6/7 (86%) | 8/9 (89%) | 14/16 (88%) | <0.0001 | 0.131 |
aSterile protection: mice that remain parasite-free (via microscopic blood-smear monitoring) throughout the experimental time course.
bBarnard’s exact test p values shown were not adjusted for multiple comparisons due to small group sizes and a small number of predefined comparisons being made.
cmIgG: normal mouse IgG control
dindicates results previously reported in Kisalu et al.55.
Mice were injected with indicated doses of either nonspecific mIgG, anti-CSP mAb CIS43, anti-PfTRAP mAb AKBR-4, or a combination of anti-CSP and AKBR-4 24 h prior to challenge with five Pf-infected mosquitoes. Mice were injected with human red blood cells on days 5 and 6, and then blood was sampled on days 7 and 9 to detect blood-stage parasitemia by qRT-PCR. The number and percentages of mice protected across three independent experiments are shown.